GlassScriptPhysician profile
Nikolajs Lapins
NPI 1346247228
$5,018.22
in general payments reported to CMS, 2019-2025
24 companies · $1,311 in 2025
The $1,311 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $855 · 2020: $688 · 2021: $437 · 2022: $851 · 2023: $598 · 2024: $278 · 2025: $1,311.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,997 · Education: $190.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,996.92 |
| Education | $190.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $881.51 | 2019-2025 | Tremfya, Simponi, Simponi Aria |
| Abbvie INC. | $609.95 | 2019-2025 | |
| Genzyme Corporation | $494.43 | 2019-2024 | |
| Regeneron Healthcare Solutions, INC. | $455.70 | 2019-2025 | Dupixent |
| Incyte Corporation | $410.97 | 2021-2025 | Opzelura |
| Lilly USA, LLC | $401.64 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Galderma Laboratories, L.P. | $389.84 | 2019-2025 | Nemluvio |
| Leo Pharma INC. | $280.90 | 2019-2025 | Anzupgo, Adbry |
| Pfizer INC. | $238.96 | 2019-2023 | |
| Sun Pharmaceutical Industries INC. | $181.74 | 2019-2024 | Winlevi, Absorica Ld, Ilumya |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $141.48 | 2019-2025 | Jublia, Cabtreo, Siliq |
| Organon LLC | $93.00 | 2025 | Vtama |
| Amgen INC. | $89.42 | 2019-2023 | Otezla |
| Novartis Pharmaceuticals Corporation | $75.97 | 2019-2025 | |
| Biofrontera INC. | $59.77 | 2019-2025 | Xepi, Bf-Rhodoled, Ameluz |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermira, INC. | $38.28 | 2019-2020 | |
| Dusa Pharmaceuticals, INC. | $31.20 | 2019 | |
| Ucb, INC. | $30.38 | 2025 | Bimzelx |
| Vyne Pharmaceuticals INC. | $22.48 | 2020 | |
| Aclaris Therapeutics, INC. | $20.59 | 2019 | |
| Epi Health, LLC | $20.32 | 2019 | |
| Almirall LLC | $19.31 | 2019 | |
| Allergan, INC. | $16.48 | 2019 | |
| Sanofi-Aventis U.S. LLC | $13.90 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nikolajs Lapins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.